Proxibarbital (Ipronal) is a barbiturate derivative synthesized in 1956 in Poland by Bogusław Bobrański. It has anti-anxiety and sedative properties and is, in contrast to most barbiturates, almost without hypnotic action.[1] It was used as a sedative and anti-anxiety drug. It was also used in the treatment of migraine headaches in a similar manner to butalbital.[2] It was a prescription drug available in Poland from the 1950s to the 1990s under trade name Ipronal.

Valofane isomerizes to proxibarbal in vivo.[3]

References

  1. ↑ Zajdel P, Kulig K, Zejc A (2008). Zejc A, Gorczyca M (eds.). Chemia leków, podręcznik dla studentów farmacji i farmaceutów [Drug chemistry, textbook for pharmacy students and pharmacists] (in Polish). Warszawa, Poland. ISBN 978-83-200-3652-7.{{cite book}}: CS1 maint: location missing publisher (link)
  2. ↑ Sulman FG, Pfeifer Y, Tal E (December 1976). "[Migraine therapy by enzyme induction with proxibarbital]". Therapie der Gegenwart (in German). 115 (12): 2088–103. PMID 14412.
  3. ↑ Lambrey B, Compagnon PL, Jacquot C (1981). "Pharmacokinetics of 14C-2-allophanyl-2-allyl -gamma-valero-lactone: a prodrug of proxibarbal in rats". European Journal of Drug Metabolism and Pharmacokinetics. 6 (3): 161–9. doi:10.1007/BF03189485. PMID 6118275. S2CID 10197120.
source: https://en.wikipedia.org/wiki/Proxibarbital